These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7516377)

  • 1. [Doxazosin in the treatment of benign prostatic hypertrophy].
    Rollema HJ; Janknegt RA
    J Urol (Paris); 1993; 99(6):314-5. PubMed ID: 7516377
    [No Abstract]   [Full Text] [Related]  

  • 2. [Single-blind study of the effect of doxazosin mesylate in benign prostatic hypertrophy].
    Siracusano S; Paoni A; Tomasi PA; Deriu M; Trombetta C; Belgrano E
    Prog Urol; 1994 Dec; 4(6):1017-21. PubMed ID: 7533030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety in the use of doxazosin (cardura) in the treatment of patients with benign prostatic hypertrophy (bph)].
    Lopatkin NA; Aliaev IuG; Kogan MI; Loran OB; Mazo EB; Stepanov VN
    Urologiia; 2003; (5):3-4. PubMed ID: 14658262
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia.
    Kirby RS
    Scand J Urol Nephrol Suppl; 1995; 168():29-33. PubMed ID: 7541549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of doxazosin in patients with benign prostatic hyperplasia.
    Janknegt RA
    Scand J Urol Nephrol Suppl; 1995; 168():21-7. PubMed ID: 7541548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxazosin: a new approach to hypertension and benign prostatic hyperplasia.
    Pool JL
    Br J Clin Pract; 1996; 50(3):154-63. PubMed ID: 8733335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
    Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
    Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
    Dutkiewicz S
    Mater Med Pol; 1996; 28(3):93-102. PubMed ID: 9167419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morning versus evening dosing with doxazosin in benign prostatic hyperplasia: pharmacokinetics, efficacy and safety.
    Kirby RS
    Int J Clin Pract; 1998 Mar; 52(2):75-7. PubMed ID: 9624784
    [No Abstract]   [Full Text] [Related]  

  • 10. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
    Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
    Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
    Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    BJU Int; 2008 Nov; 102 Suppl 2():3-7. PubMed ID: 19032603
    [No Abstract]   [Full Text] [Related]  

  • 13. Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
    Hernandez C; Duran R; Jara J; Castaño I; Moralejo M
    Prostate Cancer Prostatic Dis; 2005; 8(4):375-80. PubMed ID: 16264771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia.
    Ng CF; Wong A; Cheng CW; Chan ES; Wong HM; Hou SM
    J Urol; 2008 Sep; 180(3):1042-6. PubMed ID: 18639296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
    Dutkiewicz S
    Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tonocardin (doxazosin) in treating lower urinary tract symptoms].
    Mazo EB; Chepurov DA
    Urologiia; 2003; (3):15-6. PubMed ID: 12846089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
    Roehrborn CG; Siegel RL
    Urology; 1996 Sep; 48(3):406-15. PubMed ID: 8804494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
    Gerber GS; Contreras BA; Zagaja GP; Kim JH; Steinberg GD; Rukstalis DB
    Urology; 1997 Aug; 50(2):229-33. PubMed ID: 9255293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.